Kodiak Sciences (KOD) Operating Leases (2019 - 2026)
Kodiak Sciences' (KOD) quarterly Operating Leases came in at $44.3 million in Q1 2026, down 21.8% YoY from $56.7 million in Q1 2025, and down 5.91% on a QoQ basis from $47.1 million in Q4 2025.
Kodiak Sciences (KOD) Operating Leases (2019 - 2026) Analysis & Trends
Kodiak Sciences (KOD) has 8 years of Operating Leases data on file, last reported at $44.3 million in Q1 2026.
- Quarterly Operating Leases fell 21.8% year-over-year to $44.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $44.3 million (down 21.8% YoY) and the FY2025 annual result came in at $47.1 million, down 21.1% from the prior year.
- Operating Leases fell to $44.3 million in Q1 2026, from $47.1 million in the prior quarter.
- In the past five years, Operating Leases ranged from a high of $81.0 million in Q2 2022 to a low of $6.8 million in Q2 2023.
- A 5-year average of $62.1 million and a median of $65.9 million in 2024 frame the typical range for Operating Leases.
- Annual changes were most pronounced in 2023 — Operating Leases plunged 91.6% — and 2024, when it jumped 868.66%.
- Tracing KOD's Operating Leases over 5 years: stood at $77.8 million in 2022, then dropped by 7.64% to $71.9 million in 2023, then fell by 16.9% to $59.7 million in 2024, then dropped by 21.1% to $47.1 million in 2025, then dropped by 5.91% to $44.3 million in 2026.
- The last three Operating Leases figures came in at $44.3 million (Q1 2026), $47.1 million (Q4 2025), and $50.4 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Kodiak Sciences | 2.60 Bn | 2.60 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 42.95 Mn |
| Mar 31, 2026 | 44.33 Mn |
| Dec 31, 2025 | 47.12 Mn |
| Sep 30, 2025 | 50.45 Mn |
| Jun 30, 2025 | 53.92 Mn |
| Mar 31, 2025 | 56.69 Mn |
| Dec 31, 2024 | 59.72 Mn |
| Sep 30, 2024 | 63.24 Mn |
| Jun 30, 2024 | 65.87 Mn |
| Mar 31, 2024 | 68.72 Mn |
| Dec 31, 2023 | 71.86 Mn |
| Sep 30, 2023 | 74.46 Mn |
| Jun 30, 2023 | 6.80 Mn |
| Mar 31, 2023 | 78.81 Mn |
| Dec 31, 2022 | 77.81 Mn |
| Sep 30, 2022 | 78.70 Mn |
| Jun 30, 2022 | 80.99 Mn |
| Mar 31, 2022 | 76.42 Mn |
| Dec 31, 2021 | 76.06 Mn |
| Sep 30, 2021 | 77.34 Mn |